Infant Bacterial Therapeutics AB

IBT-B.ST · Health Technology · Pharmaceuticals: Major · SE

8 employees · ibtherapeutics.com

About

Infant Bacterial Therapeutics AB develops IBP-9414, a drug candidate containing Lactobacillus reuteri, for preventing necrotizing enterocolitis (NEC) in premature infants. The company focuses on clinical development of this treatment, targeting a rare disease with high unmet medical need. Its primary customers are healthcare providers and hospitals treating premature infants, particularly in neonatal intensive care units. The company operates as a clinical stage pharmaceutical firm, with its main product in development for a specific patient segment. The firm's revenue model relies on future drug sales once IBP-9414 receives regulatory approval. It does not generate current revenue from product sales as it remains in clinical development. The company's focus on NEC prevention positions it within the rare disease treatment market, targeting a niche segment of premature infants requiring specialized care. IBP-9414 is developed to address a fatal condition with no current effective treatment options.

Annual results

Reported figures, SEK

YearRevenueNet incomeNet marginFree cash flow
2025—-65.0M——
2024—-136M——
2023—-123M——
2022—-65.0M——
2021—-44.0M——

IBT-B.ST in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Infant Bacterial Therapeutics AB are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Infant Bacterial Therapeutics AB (IBT-B.ST) — company profile and financials · MarketPulse